These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. Kim HJ; Yoo HS; Kim JC; Park CS; Choi MS; Kim M; Choi H; Min JS; Kim YS; Yoon SW; Ahn JK J Ethnopharmacol; 2009 Jul; 124(2):189-96. PubMed ID: 19409970 [TBL] [Abstract][Full Text] [Related]
5. Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus. Ma Y; Nakamoto S; Ao J; Qiang N; Kogure T; Ogawa K; Nakagawa M; Fujiwara K; Iwanaga T; Kojima R; Kanzaki H; Koroki K; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Nakagawa R; Ogasawara S; Muroyama R; Chiba T; Kato J; Kato N Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233317 [TBL] [Abstract][Full Text] [Related]
6. [The inhibitory effects on hepatitis B virus replication by stable expression of DN mutants of hepatitis B virus X gene pRev X-GFP]. Song JW; Lin JS; Kong XJ; Liang KH Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):392-4. PubMed ID: 15268799 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus X protein modulates remodelling of minichromosomes related to hepatitis B virus replication in HepG2 cells. Luo L; Chen S; Gong Q; Luo N; Lei Y; Guo J; He S Int J Mol Med; 2013 Jan; 31(1):197-204. PubMed ID: 23128981 [TBL] [Abstract][Full Text] [Related]
8. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Lucifora J; Arzberger S; Durantel D; Belloni L; Strubin M; Levrero M; Zoulim F; Hantz O; Protzer U J Hepatol; 2011 Nov; 55(5):996-1003. PubMed ID: 21376091 [TBL] [Abstract][Full Text] [Related]
10. Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. Jaitovitch-Groisman I; Fotouhi-Ardakani N; Schecter RL; Woo A; Alaoui-Jamali MA; Batist G J Biol Chem; 2000 Oct; 275(43):33395-403. PubMed ID: 10934196 [TBL] [Abstract][Full Text] [Related]
11. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. Zhang JF; Xiong HL; Cao JL; Wang SJ; Guo XR; Lin BY; Zhang Y; Zhao JH; Wang YB; Zhang TY; Yuan Q; Zhang J; Xia NS Theranostics; 2018; 8(2):549-562. PubMed ID: 29290826 [No Abstract] [Full Text] [Related]
12. Inhibition of hepatitis B virus replication by the internal fragment of hepatitis B core protein. Han J; Pan X; Gao Y; Weil L Virus Res; 2010 Jun; 150(1-2):129-34. PubMed ID: 20303370 [TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. Leupin O; Bontron S; Schaeffer C; Strubin M J Virol; 2005 Apr; 79(7):4238-45. PubMed ID: 15767425 [TBL] [Abstract][Full Text] [Related]
15. Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches. Kumar M; Follenzi A; Garforth S; Gupta S Antivir Ther; 2012; 17(3):519-28. PubMed ID: 22300804 [TBL] [Abstract][Full Text] [Related]
16. Latest developments in the treatment of hepatitis B. Dandri M; Petersen J Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309 [TBL] [Abstract][Full Text] [Related]
17. Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. Chi WJ; Doong SL; Lin-Shiau SY; Boone CW; Kelloff GJ; Lin JK Carcinogenesis; 1998 Dec; 19(12):2133-8. PubMed ID: 9886568 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell. Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501 [TBL] [Abstract][Full Text] [Related]
19. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells. Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586 [TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]